Secondary outcomes
SECONDARY
Key secondary end points were achieved for both the DB 100 mg and 80 mg resmetirom arms. At week 24, resmetirom treatment resulted in significant reductions in atherogenic lipid levels from baseline compared to placebo treatment (Fig. 